New Zealand - English - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - alginic acid 250mg;  ;  ; aluminium hydroxide gel dried 50mg;  ;  ;  ; magnesium trisilicate hydrate 12.5mg; sodium bicarbonate 85mg - chewable tablet - active: alginic acid 250mg     aluminium hydroxide gel dried 50mg       magnesium trisilicate hydrate 12.5mg sodium bicarbonate 85mg excipient: calcium carbonate citrus limon magnesium stearate mannitol povidone saccharin sodium xylitol

New Zealand - English - Medsafe (Medicines Safety Authority)

reckitt benckiser (new zealand) limited - alginic acid 250mg;  ;  ; aluminium hydroxide gel dried 50mg;  ;  ;  ; magnesium trisilicate hydrate 12.5mg; sodium bicarbonate 85mg - chewable tablet - active: alginic acid 250mg     aluminium hydroxide gel dried 50mg       magnesium trisilicate hydrate 12.5mg sodium bicarbonate 85mg excipient: calcium carbonate magnesium stearate mannitol peppermint oil povidone saccharin sodium vanillin xylitol

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium bicarbonate; calcium carbonate - chewable tablet - 250 mg/106.5 mg/187.50 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium bicarbonate; calcium carbonate - oral suspension in sachet - 500 mg/10 ml + 213 mg/10 ml + 325 milligram/ 10 millilitre - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium bicarbonate; calcium carbonate - oral suspension in sachet - 500 mg+267 mg+160 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium hydrogen carbonate; calcium carbonate - chewable tablet - 250 mg/133.5 mg/80 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - sodium alginate; sodium hydrogen carbonate; calcium carbonate - chewable tablet - 250 mg/133.5 mg/80 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - alginic acid; calcium carbonate; magnesium carbonate - chewable tablet - 625/73.5/150 milligram(s) - combinations and complexes of aluminium, calcium and magnesium compounds

Ireland - English - HPRA (Health Products Regulatory Authority)

reckitt benckiser ireland ltd - potassium bicarbonate; sodium alginate - chewable tablet - 500/100 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

United States - English - NLM (National Library of Medicine)

mylan institutional inc. - nitrofurantoin monohydrate (unii: e1qi2cqq1i) (nitrofurantoin - unii:927ah8112l), nitrofurantoin (unii: 927ah8112l) (nitrofurantoin - unii:927ah8112l) - nitrofurantoin 75 mg - nitrofurantoin capsules, usp (monohydrate/macrocrystals) are indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of escherichia coli or staphylococcus saprophyticus . nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. to reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (monohydrate/macrocrystals)and other antibacterial drugs, nitrofurantoin capsules (monohydrate/macrocrystals)should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. nitrofurantoins lack the broader tissue distribution of other therapeutic age